Gemtuzumab Ozogamicin

Category: Cancer



Gemtuzumab Ozogamicin Overview

Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg) is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myeloid leukemia from 2000 to 2010. It was withdrawn from market in June 2010 when a clinical trial showed the drug increased patient death and added no benefit over conventional cancer therapies. It was re-introduced into the US market in 2017.[1] Contents 1 Mechanism and side effects 2 History 3 See also 4 References Me...

Read more Gemtuzumab Ozogamicin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Gemtuzumab_ozogamicin

Recent Gemtuzumab Ozogamicin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Gemtuzumab Ozogamicin
  • Injection: 5mg, 5mg/vial
  • Vial: 4.5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Gemtuzumab Ozogamicin or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 17 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA